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Complement activation in rabbit plasma has been found to result in the generation 
of a  factor which  is  able  to  increase  microvascular permeability by a  mechanism 
independent of histamine release. Evidence has been obtained that this factor corre- 
sponds with the major chemotactic factor (1) in complement-activated rabbit plasma, 
C5a,  probably devoid of its carboxyl terminal  arginine  (2,  3).  This substance was 
found to produce little plasma  exudation when  injected alone into skin.  However, 
when mixed with a vasodilator prostaglandin (PG) (PGE1, PGE2, or PGI2),  1 C5a was 
found to be more potent at inducing plasma exudation than either of the established 
permeability-increasing agents, histamine or bradykinin. This interdependence of two 
types of mediator, a vasodilator (with no action on permeability) and a permeability- 
increasing substance (with no vasodilator activity) may explain why rabbit C5a has 
not  previously been  associated  with  increased  vessel  wall  permeability.  Generally, 
complement activation is thought to lead to increased vascular permeability because 
of histamine released from mast cells and basophils by the anaphylatoxins C3a and 
C5a  (4-6).  The  finding that  C5a can  increase vascular permeability by an  action 
independent of histamine release, considerably extends the potential importance of 
C5a in inflammatory edema because, in this respect, histamine has a very limited role 
in most clinical and experimental situations. 
It  is  proposed  that  C5a,  although  discovered originally because  of its  systemic 
effects from which its trivial name anaphylatoxin is derived (7), has evolved as a local 
hormone whose extravaseular generation can mediate the local accumulation of fluid 
and  leukocytes. In this way, C5a can control local complement-mediated lysis  and 
phagocytosis of microorganisms in tissues, Both local fluid accumulation and leukocyte 
accumulation  in  response  to  C5a  suggest  an  intimate  relationship  between  this 
substance and vascular endothelial cells. 
Preliminary results of this investigation have been described previously (8, 9). 
Materials and Methods 
Animals.  Male New Zealand white rabbits,  3.5-4 kg body wt, were used in all experiments. 
Measurement of Plasma Exudation in Rabbit Skin.  Plasma exudation in skin was measured as the 
* Supported by the Medical Research Council and the Vandervell Foundation, England. 
t Abbreviations used in this paper: BSA, bovine serum albumin; CM, carboxymethy[; EDr,0, mean effective 
dose;  OA, ovalbumin; PAPA, plasma activation permeability agent; PG, prostaglandin; PMN, polymor- 
phonuclear; SBTI, soybean trypsin inhibitor; SDS, sodium dodecyl sulfate; ThG, thyroglobu[in. 
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•  •  •  131  •  •  •  accumulation of intravenously  injected  I-human serum albumin, as previously described (10, 
11). -15/xCi/kg body wt of 131I-human serum albumin, mixed with 2 ml of 2.5% wt:vol Evans 
blue dye in 0.9% saline, was injected via the marginal ear vein of the rabbit• This was followed 
by an intravenous injection of a short acting anesthetic, methohexitone sodium (~ 10 mg/kg). 
Intradermal injections (0.1-ml vol) of test materials were then administered into the previously 
clipped back skin. Injections were given in random order according to a balanced site pattern. 
Up to 14 test materials, each having 6 replicates, were injected into each rabbit. After 30 min 
the animal was killed by an overdose  of pentobarbltone sodium, and 1-ml blood samples were 
taken three times by cardiac puncture. The back skin was then removed and the injection sites 
punched out  using a  16-mm diameter steel  punch. The skin and blood samples were  then 
counted in an automatic gamma spectrometer. The skin sample counts were divided by the 
count of 1/tl of blood plasma so that exudate volumes could be expressed  in terms of microliters 
of plasma (11). 
The time-course of the response to intradermally  injected zymosan was measured by injecting 
zymosan at different intervals before the intravenous injection of labeled albumin; exudation 
was then measured over a period of 30 rain. The effect of vasodilator PG on these responses was 
determined by injecting the PG (100 ng/0.1 ml injection) into the skin sites immediately after 
intravenous injection  of labeled albumin; the PG routinely used in these experiments was PGE1. 
Pharmacological inhibitors or antagonists were injected locally. 
Measurement of Changes in Blood Flow in Rabbit Skin.  Changes in blood flow were measured in 
rabbit skin using a multiple site radioactive xenon clearance technique (10, 11). Test samples 
were  mixed  with  solutions of  la3Xe to  give  an  activity of 5-10 /~Ci/0.1  ml  and  injected 
intradermally as above. Animals were killed after a period of 20 rain, the skin was removed and 
the injection sites punched out. Skin samples and samples of injection fluids were stored under 
paraffin oil in sealed tubes for counting• Results, expressed as percentage increased or decreased 
blood flow with respect  to saline-injected control sites, were calculated as previously described 
(11). 
Activation of Plasma.  Small volumes of blood (up to 30 ml) were collected into heparin (10 
U/ml) from the marginal ear veins of conscious rabbits. Larger volumes were obtained from 
the cannulated carotid artery of anesthetized rabbits (pentobarbitone sodium, ~30 mg/kg). 
Blood was centrifuged for 25 min at 1,900 g and the plasma removed. Zymosan was suspended 
in 0.9% saline at a concentration of 10 mg/ml (except where otherwise stated in the text), and 
0.1 ml of this suspension was added to every 1 ml of plasma. Plasma was incubated at 37°C for 
30 rain in a shaking water bath. Control plasma was incubated in the same way with 0.1 ml of 
saline per  1 ml of plasma. Test and control plasma samples were centrifuged for  20 min at 
1,900 g. The supernates were removed and tested immediately, fractionated at 2°C, or stored 
at -20°C. 
Fractionation of Plasma.  All steps  were carried out at  2°C.  Use of glassware  was avoided 
except for chromatography columns which were siliconized before use. 
Plasma was acidified to pH 5.5-6.0 by slowly adding 0.2 M sodium acetate hurler, pH 3.8, 
centrifuged, and applied to columns (1.5  X  2 cm)  of carboxymethyl (CM)-Sephadex  C-25 
equilibrated in 0.9% saline:0.1  M  sodium acetate  buffer pH  6.0  (5:1).  At  least  100  ml  of 
activated plasma could be passed through a single column without any permeability-increasing 
activity emerging in the effluent. The columns were washed with 40 ml sallne:sodium acetate 
buffer pH  6.0,  and  the  permeability-increasing factor  was  then  eluted  with  30  ml 0.5  M 
ammonium formate. The lyophilized ammonium formate fraction was chromatographed in an 
upward direction on columns of Sephadex  gel  filtration media.  For analytical purposes,  a 
column (1.5 x  87 cm) of Sephadex G-75 superfine in 0.9% saline was used. For preparative 
procedures, a column (2.5 X 70 cm) of Sephadex G-100 in 0.9% saline:0.2 M  sodium acetate 
buffer, pH 3.8  (9:1), was used; fractions with permeability-increasing  activity (or equivalent 
fractions from  plasma incubated in the absence of zymosan) were  pooled and lyophilized. 
Excess salt was removed using a column (1.5 ×  5 cm) of Sephadex G-25 M  in saline:sodium 
acetate buffer pH 3.8, and preparations were stored at -20°C. For biological testing, portions 
were removed, neutralized with sodium hydroxide, and diluted with 0.9% saline:0.2 M sodium 
phosphate buffer pH 7.2 (9:1). Protein concentrations were determined using a turbidometric 
tannin micromethod (12). In some experiments (as indicated in the text), the ion-exchange step 138  HISTAMINE-INDEPENDENT ACTION OF  RABBIT C5a 
was omitted, and whole plasma was chromatographed on columns of Sephadex G-100 (2.6 × 
65 era) in 0.9% saline. 
Columns  of Sephadex  gels were calibrated  using the  following  proteins with  molecular 
weights  (13) as indicated:  bovine serum albumin  (BSA, 67,000); ovalbumin  (OA,  45,000); 
soybean trypsin inhibitor  (SBTI, 21,500); bovine pancreas ribonuclease A  (RNase,  13,700); 
and glucagon  (3,500). The void volume was  determined using bovine thyroglobulin  (ThG, 
670,000) and the salt peak with ammonium formate. 
Materials.  Mepyramine maleate and pentobarbitone sodium were purchased from May and 
Baker Ltd., Dagenham, Essex, United Kingdom; methohexitone sodium from Eli Lilly & Co., 
Windlesham,  Surrey,  United  Kingdom;  heparin  sodium  from  Duncan,  Flockhart  &  Co., 
London, United Kingdom; Evans Blue dye from Searle  Diagnostics,  High Wycombe, Buck- 
inghamshire, United  Kingdom; histamine acid phosphate from British  Drug Houses,  Ltd., 
Poole, Dorset, United Kingdom; Trasylol (aprotonin) from Bayer UK Limited, Pharmaceutical 
Division, Haywards Heath, West Sussex, United Kingdom; bradykinin triacetate, norepineph- 
rine bitartrate, prostaglandins E1 and E2, SBTI, zymosan (zymosan A, from S. cerevisiae), and 
proteins for calibrating gel filtration columns from Sigma Chemical Co., Poole, Dorset, United 
Kingdom; Sephadex gel filtration and ion exchange materials from Pharmacia Fine Chemicals, 
Hounsiow, Middlesex,  United Kingdom; lSlI-human serum albumin and lSSXe in saline from 
The Radioehemieal Centre, Amersham, Buckinghamshire, United Kingdom. 
The following were gifts: hog C5a from Professor W. Vogt, Max Planek Institut, G6ttingen, 
German Federal Republic; glucagon from Dr. W. Dawson,  Eli Lilly & Co.; mammalian tissue 
kailikrein  (Glumorin) from Bayer; and indomethacin from Merck, Sharp & Dohme, Hoddesdon, 
Hertfordshire, United Kingdom. 
Results 
Involvement of Endogenous PG in  Plasma  Exudation  Induced by  Intradermal  Injections  of 
Zymosan.  Fig.  1 shows the time-course of the rate of plasma exudation after intrader- 
mal  injection  of zymosan  in  the  rabbit.  Zymosan  was  injected  intradermally  at 
intervals before an intravenous injection of x~lI-albumin, and plasma exudation was 
then  measured  over  periods  of 30  rain  as  shown  on  the  abscissa.  Little  plasma 
exudation was apparent during the first 30 min. Peak exudation rate was between  1 
and 3 h; exudation then declined reaching negligible rates by 5 h. Local injection of 
the PG synthesis inhibitor, indomethacin, effectively suppressed plasma exudation, as 
shown.  PGE1  (PGE2 and PGI2 showed similar activity) potentiated exudation when 
injected locally immediately after intravenous injection of labeled albumin. Interest- 
ingly, potentiation was elicited by PG during the first 30 min, at a time when zymosan 
alone  produced  negligible  exudation.  PG  injected  alone  produced  little  plasma 
exudation,  as shown.  In spite of the observation that  indomethacin  suppressed  the 
response  to  zymosan,  indomethacin  had  no  effect  on  the  zymosan  response  when 
potentiated by PGE1. 
These observations can be explained in the following manner. Zymosan stimulates 
the  generation  of two  substances  in  the  skin,  neither  of which  induces  significant 
plasma exudation alone. The first substance increases the permeability of blood vessel 
walls, and the second produces vasodilatation and potentiation of plasma exudation. 
(Evidence that vascular permeability is increased before the generation of vasodilator 
mediator has been presented previously [11].)  The endogenous vasodilator substance 
appears  to  be  a  PG;  indomethacin  inhibits  its  synthesis,  removes  its  potentiating 
activity,  and  thus  suppresses  plasma exudation.  Indomethacin,  however,  does  not 
suppress the generation of  endogenous permeability-increasing mediator, so that PGE1 
is still able to potentiate plasma exudation even in the presence of indomethacin. 
Contribution of Histamine  and Bradykinin  to  Zymosan-induced Edema.  The  results  de- 100' 
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Fro.  1.  Time-course of zymosan-induced plasma exudation. Zymosan  (Z;  100/lg/0.l  ml)  was 
injected iotradermally at various intervals before an intravenous injection of 1all-albumin. Drugs or 
saline were then injected locally in 0. l-ml vol, and exudation was measured over periods of 30 min 
as shown on the abscissa. Exudation  reached a  peak  1-3 h after  injection of zymosan. Local 
injections of indomethacin (Indo; 1/~g added to the zymosan and a further 1 #g immediately after 
administration of isotope) suppressed the plasma exudation induced by zymosan. Local injection of 
PGE1 (100 ng/0.1 ml administered immediately after isotope injection) potentiated the exudation 
response to zymosan. Each point represents the mean :1: SEM of  six replicate injections. The dashed 
line represents the response to two injections of saline with a 60-min inte/'val; the small increase 
produced by addition of PGE~ to the second injection is shown. 
scribed above indicate that a  substance is generated in the skin which acts synergis- 
tically  with  endogenous,  or  exogenous,  vasodilator  PG  to  produce  inflammatory 
edema.  Because  both  histamine  and  bradykinin  are  potent  vascular  permeability- 
increasing  substances  whose effects can  be  similarly  enhanced  by PG  (14,  15),  the 
possibility  that  these  substances  are  generated  in  the  skin  was  investigated.  Fig.  2 
shows the effects of a  locally injected antihistamine,  mepyramine maleate  (an antag- 
onist  of Ha receptors), on zymosan-induced plasma  exudation  in rabbit  skin.  From 
the results,  it  is clear that  the antihistamine  produced only a  limited suppression  of 
plasma  exudation.  Mepyramine  was  equally  ineffective  in  suppressing  potentiated 
responses produced  by zymosan and  PGE1.  On the contrary, responses to intrader- 
mally injected histamine and responses to histamine mixed with PGEa were effectively 
suppressed  by mepyramine.  These results indicate that the receptors involved in the 
enhanced vascular permeability responses to histamine in rabbit skin are Ht receptors, 
but that histamine is unlikely to be a  major permeability-increasing mediator gener- 
ated in response to zymosan. 
Similar  experiments  were  carried  out  using  aprotonin  (Trasylol),  which  inhibits 
kinin  formation by tissue and plasma kallikreins.  This drug produced no significant 
inhibition  of  the  responses  to  zymosan,  or  zymosan  and  PGE1,  but  suppressed 140  HISTAMINE-INDEPENDENT ACTION  OF  RABBIT  C5a 
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FIc.  2.  The effect  of mepyramine on zymosan-induced  plasma  exudation.  Zymosan (Z;  I00 ~g/ 
0.1  ml)  was injected  60  min before (60-  to 90-min  response) or immediately  after  (0-  to  30-rain 
response) an intravenous  mject~on'  "  '  of ~3~i_albumln,. and exudation was measured over a period of 30 
min. Sites treated with mepyramine are shown as shaded columns. Mepyramine maleate (1 #g base/ 
0.1  ml) was injected  mixed with the zymosan; in the case of the 60-  to 90-min response, a  further 
intradermal injection was given immediately after the intravenous injection of isotope. The effect of 
mepyramine on the 0- to 30-rain response to histamine (H; 2.5 #g/0.1  ml) is shown for comparison. 
All treatments were tested with and without PGEI (100 ng/0.1 ml injected immediately after isotope 
administration).  Responses  to  zymosan, with and  without  PGE~,  were resistant  to  mepyramine 
treatment.  In  this  experiment,  the  only  response to  zymosan  that  was  significantly  (unpaired 
Student's t test)  affected by mepyramine was that for 0-30 rain without PGEI. In two of a further 
six experiments, mepyramine produced a small significant  reduction of the later part of the response. 
In contrast, mepyramine virtually abolished the responses to histamine, with and without PGEI, in 
all  experiments. Each column represents the mean +  SEM of six replicate injections. The dashed 
line represents the response to two injections of saline (Sal) with a 60-rain interval. 
responses to a standard preparation of tissue kallikrein (Fig.  3). These results suggest 
that kinins are not involved in the response to zymosan. 
Generation of a  Vascular Permeability-increasing Factor in  Blood Plasma during Incubation 
with Zymosan.  The possibility that the unknown endogenous permeability-increasing 
mediator was a  product  of blood plasma was investigated  by  testing rabbit  plasma 
after incubation with zymosan. Fresh plasma was incubated for 30 min with zymosan 
at concentrations up to  10 mg/ml, and the zymosan was removed by centrifugation. 
Samples  of plasma  were  then  injected  into  rabbit  skin  and  responses,  in  terms  of 
plasma exudation, measured over a period of 30 min. As shown in Fig. 4, no significant 
plasma exudation  was produced  by  these plasma samples.  When  PGE1  was mixed 
with  these  samples,  plasma  which  had  been  incubated  with  zymosan  produced 
marked dose-related plasma exudation whereas plasma incubated  without  zymosan 
produced  little plasma exudation.  The activity generated  in the plasma  (designated 
PAPA or plasma activation permeability agent  [8, 9])  was similar to the endogenous 
permeability-increasing mediator generated in skin in response to injected zymosan in 
that  PAPA  produced  significant  plasma exudation  only when  in  the presence of a 
vasodilator PG.  It is clear that, whereas injection of zymosan into skin results in the T. J.  WILLIAMS AND  P. J. JOSE  141 
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Fic.  3.  The effect of Trasylol on zymosan-induced plasma exudation.  Zymosan (Z;  100/~g/0. I 
ml) was injected 60 min before (60- to 90-min response) or immediately after (0- to 30-min response) 
an intravenous injection of =all-albumin,  and exudation was measured over a period of 30 min. Sites 
treated with Trasylol are shown as shaded columns. Trasylol (1 #g/0.1 ml) was injected mixed with 
the zymosan; in the case of the 60- to 90-min response, a further intradermal injection was given 
immediately after the intravenous injection of isotope. The effect of Trasy[ol on the 0- to 30-min 
response to kallikrein (K; 150 ng/0.1 ml) is shown for comparison. All treatments were tested with 
and without PGE, (100 ng/0.1 ml injected locally immediately after administration of isotope). 
Trasylol had no significant effect on zymosan-induced plasma exudation in the periods 0-30 and 
60-90 min with, and without, PGE]. Trasylol, however, virtually abolished the responses  to kallikrein 
with and without PGEI. Each column represents the mean + SEM of six replicate injections.  The 
dashed line represents the response to two injections of saline (Sal) with a 60-min interval. 
generation of permeability-increasing activity and vasodilator activity, intradermal 
injection of  zymosan-activated plasma  produces  only  the  permeability-increasing 
activity. For this reason, in all subsequent experiments, samples derived from zymosan- 
activated plasma were mixed with the vasodilator PGE] before testing in the skin. 
The generation of permeability-increasing  activity was inhibited by either heating 
the  plasma  at  56°C  for  30  min  or  addition  of  EDTA  (10  mM,  pH  7.4)  before 
incubation with  zymosan.  The  same  heat  treatment  or  addition  of  EDTA  after 
removal of zymosan had no effect on activity. Addition of EGTA (10 mM, pH  7.4), 
Trasylol (100 #g/ml), or SBTI (100/.tg/ml) before incubation with zymosan did not 
inhibit the generation of permeability-increasing  activity. The response to activated 
plasma  (and  to  histamine and bradykinin) varied  between individual rabbits, but 
permeability-increasing  activity was observed in each of 54 different plasma samples 
activated with zymosan (1 mg/ml) tested in the same number of rabbits. No difference 
between homologous and autologous plasma samples was observed. 
Demonstration that PAPA Has an Action Independent of Histamine  Release.  The results 
described above suggest that PAPA could be an anaphylatoxin generated by activa- 
tion  of the  complement  system.  Most  previous  work  suggests  that  anaphylatoxin 142  HISTAMINE-INDEPENDENT  ACTION  OF  RABBIT  CSa 
~P~osmo 
+ 
200 
E 
_c 
o. 
-~  IOC 
...........  ~  PLasma  i:  .... 
.... ~.  ...........  ~~  ....  ~  .... 
r--  ....  ,  -,r-  --r*" 
0  0001  0.01  0.1  I  10 
Zymoson  (mg/ml p[asmo}  PGE  I  sol 
FIG.  4.  The generation of permeability-increasing activity by incubation of blood  plasma with 
zymosan. Heparinized  rabbit  plasma was  incubated  for  30  min  at  37°C  with  various doses of 
zymosan, centrifuged to remove the zymosan, and injected intradermally with, or without, PGEI 
(100 ng/0.1  ml). Plasma exudation was measured by the accumulation of previously administered 
l:~I-albumin over a  period of 30 min. Plasma incubated with zymosan produced a  marked dose- 
related plasma exudation when tested in the presence of PGE]; plasma incubated without zymosan 
produced only a small response in the presence of PGE]. No exudation was produced by any of the 
plasma samples tested  in  the  absence of PGE].  Each  point  represents the  mean  ±  SEM  of six 
replicate injections. The dashed line represents the response to an injection of saline (Sal); the small 
increase produced by addition of PGEI  to saline is shown. 
increases vascular permeability by release of histamine  (4-6);  although  it  has been 
reported that responses to hog C5a are only partially dependent  on histamine when 
tested in guinea pig skin  (16).  Fig. 5 shows the results of an experiment designed to 
investigate if PAPA  increases vascular permeability by a  mechanism dependent  on 
histamine  release.  All  responses  were  measured  in  the  presence  of PGEI.  Plasma 
activated with zymosan (1  mg/ml, as in all subsequent experiments) was mixed with 
a  range of doses of the antihistamine,  mepyramine maleate, and tested in  the skin. 
Histamine (also with PGE1) was mixed with the same doses of mepyramine and tested 
in the same experiment. It is clear that mepyramine at doses of 1 and 3 #g virtually 
abolished  the response to histamine but  had  only a  limited suppressive effect on a 
matched response to activated plasma. In a  series of experiments, the suppression of 
responses by mepyramine (1  #g/0.1  ml) was 26  +  3%, n --- 21  samples of activated 
plasma (mixed with PGE1) tested in the same number of rabbits. 
The results obtained with mepyramine fulfill a further criterion necessary to suggest 
that  PAPA is the permeability-increasing mediator generated in skin in response to 
intradermally injected zymosan. 
Characterization of PAPA.  Gel filtration of zymosan-activated plasma on a column 
of Sephadex G-100 revealed a single peak of permeability-increasing activity (assayed 
in  the  presence of PGEI)  corresponding with  a  molecular weight  of  14,000-22,000 
(Fig. 6). No permeability-increasing activity was detected when plasma incubated in 
the absence of zymosan was fractionated by this procedure. 
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FIo. 5.  A comparison of the effect of mepyramine on plasma exudation produced by zymosan- 
activated plasma and by histamine, both in the presence of PGE~. Rabbit plasma was activated by 
incubation with zymosan (1 mg/ml)  for 30 min at 37°C and centrifuged to remove the zymosan. 
Activated plasma (P*), or histamine (H; 5/zg/0.1 ml), was mixed with PGEI (100 ng/0.1 ml) and 
various doses of mepyramine, and then injected intradermally. Plasma exudation was measured by 
the accumulation of previously  administered ~atl-albumin over a period of 30 rain. Activated plasma 
and histamine produced responses of similar size in the absence of mepyramine. However, mepyr- 
amine almost totally abolished the  response to histamine but  had  only a  partial  effect on the 
response to activated plasma. Each point represents the mean +  SEM of six replicate injections. 
The dashed line represents the response to an injection of saline. 
The  permeability-increasing  activity  was  completely  retained  by  the  cation  ex- 
changer CM-Sephadex C-25 at pH values of 6.0 and below, and was eluted with 0.5 
M  ammonium formate. Gel filtration of the lyophilized ammonium formate fraction 
on  a  column  of Sephadex  G-75  superfine  revealed  two  small  peaks  of material 
(detected by absorbance at 217 nm) corresponding with proteins of molecular weights 
11,000 and 18,000. Permeability-increasing activity was eluted in fractions correspond- 
ing with a molecular weight of 18,000 (Fig. 7). This value is similar to those previously 
determined  by gel filtration  for the anaphylatoxin derived from the fifth component 
of complement,  i.e.,  human C5a,  17,500 tool wt  (2), and rabbit  C5a,  15,000  tool wt 
(1). 
To obtain material  for further characterization,  PAPA was adsorbed from 400- to 
800-ml  vol of zymosan-activated plasma onto CM-Sephadex  C-25  (100 ml plasma/ 
column of 1.5  ×  2 cm), eluted  with  ammonium  formate,  pooled,  lyophilized,  chro- 
matographed  on  Sephadex  G-100,  and  concentrated  by  a  second  lyophilizati0n 
(Materials  and Methods).  Material  prepared  in this way was used  in all subsequent 
experiments. 
PAPA,  and  a  control  sample  prepared  from  plasma  which  had  been  incubated 
without zymosan, was analyzed by sodium dodecyl sulfate (SDS)-polyacrylamide gel 
electrophoresis  in  a  5-20% acrylamide  gradient  gel using a  discontinuous  Tris:HC! 
buffer system (17). The major protein band, which was absent in the control sample, 
corresponded  with  a  molecular  weight  of  13,000  with  a  mobility  between  that  of 
cytochrome c  (12,400  mol  wt)  and  ribonuclease  (13,700  mol wt).  The difference  in 
molecular weight, as determined by two different physical methods, is consistent with 
that reported for human C5a (3).  SDS-gel electrophoresis also revealed a second, but 144  HISTAMINE-INDEPENDENT ACTION OF  RABBIT  C5a 
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FIo. 6.  Gel  filtration  of zymosan-activated  plasma on  Sephadex  O-100. Rabbit  plasma was 
activated by incubation  with zymosan (1 mg/ml) for 30 rain at 37°C, centrifuged to remove the 
zymosan, and a 7-ml sample chromatographed  on a column (2.6 × 65 cm) of Sephadex G-100 in 
0.9% saline. Fractions collected were each of 5.2 ml in volume. Absorbance (extinction units [El) at 
280  nm  (---) shows two peaks. Fractions were mixed with  PGEI (100 ng/0.1  ml)  and injected 
intradermally.  Plasma exudation,  measured by the accumulation  of previously administered  lall- 
albumin over a period of 30 min, revealed a single peak of permeability-increasing  activity (O) 
corresponding with a molecular weight of 14,000-22,000. Fractions obtained from plasma incubated 
without zymosan (C)) showed no permeability-increasing activity. Each point represents the mean 
± SEM of replicate injections (n ~ 6 for fractions 42-54 from activated plasma; n = 3 for all other 
sites).lThe responses to injections of saline (Sal) (1"-1) and PGEI (A) are shown. The arrows indicate 
the positions of calibration proteins and salts (Materials and Methods). 
considerably less  intense,  protein  band  (11,000  mol  wt);  this  component  was  also 
present in the control sample. There was no detectable loss of permeability-increasing 
activity when PAPA was incubated in fresh rabbit plasma (1 h at 37°C), in phosphate- 
buffered saline pH 7.2 (4 h  at 37°C or 1 h at 56°C) or in dilute hydrochloric acid (pH 
3,  1 h  at 37°C).  Incubation at  100°C,  pH  7.2, resulted in a  30% loss of activity after 
10  min and a  total loss of activity after  1 h.  Total loss of activity was also obtained 
after  incubation  of  PAPA  with  2-mercaptoethanol  (0.1  M,  4  h  at  37°C).  These 
characteristics of PAPA are similar to those of C5a of other species (3). 
The  following  additional  studies  show  that  purified  PAPA  is  highly  active  on 
polymorphonuclear  (PMN)  neutrophils:  (a)  PAPA produces  a  dense  infiltration of 
PMN  neutrophils  when  injected  into  rabbit  skin  (T.  J.  Williams and  P.  J.  Jose. 
Unpublished data.);  (b) PAPA induces chemokinesis with mean effective dose (EDs0) 
of 1.2  ×  10 -9 M  and aggregation of human  peripheral blood PMN  neutrophils  (M. 
A.  Bray  and  A.  W.  Ford-Hutchinson.  Unpublished  data.);  and  (c)  PAPA  induces 
lysosomal enzyme release from rabbit PMN  neutrophils (ED~0,  1.4  X  10 -8 M)  (J.  P. 
Bennett.  Unpublished  data.).  Similar  activities on  leukocytes  have  been  observed 
previously with C5a in the rabbit (1,  18)  and other species (19, 20). 
Comparison of PAPA with Highly Purified Hog C5a.  Activated rabbit plasma has little 
spasmogenic activity on the guinea pig ileum. However, the results described above 
suggest that  the permeability-increasing activity generated in rabbit plasma is C5a, 
which corresponds with the classical anaphylatoxin of other species. The experiment 
shown  in  Fig. 8  was  designed to  verify further  the  identification of PAPA as C5a. T. J.  WILLIAMS  AND  P. J.  JOSE  145 
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Fro.  7.  Determination of the molecular weight of PAPA. Rabbit plasma (34 ml) was activated by 
incubation  with  zymosan  (1  mg/ml)  for  30  min  at  37°C,  centrifuged,  and  concentrated  by 
adsorption on a column (1.5 x  2 cm) of CM-Sephadex 12-25 at pH 5.5-6.0. The column was washed 
with buffer, and then PAPA was eluted with ammonium formate, lyophilized, dissolved in  1.5 ml 
saline, and chromatographed on a column (1.5 X 87 cm) of Sephadex G-75 superfine in 0.9% saline. 
Fractions collected were each of 2.0 ml in  volume. Absorbance  (extinction units [E])  at  217  nm 
(dashed line) shows a large peak in the region of the void volume and two smaller peaks at fractions 
50 and 56. The salt peak was located by absorbance at 234 nm (dotted line). Fractions were diluted 
threefold  with  saline,  mixed  with  PGE:  (100  ng/0.1  ml),  and  injected  intradermally.  Plasma 
exudation (O), measured by the accumulation of previously administered Is]I-albumin over a period 
of 30 rain, showed a  peak of activity corresponding with the small absorbance peak at fraction 50. 
Each point represents the mean ±  SEM of replicate injections (n =  6 for fractions 48-56; n -  3 for 
all other sites). The response to saline was 10.8 ±  0.4/~1 and that to PGEj  14.0 +  0.9/~1. The upper 
part of the figure shows a plot of molecular weight vs. fraction number for some calibration proteins 
(Materials and Methods). The molecular weight of PAPA is estimated by gel filtration to be 18,000. 
PAPA was compared with a standard preparation of hog C5a (supplied by Professor 
W. Vogt) that was purified on the basis of its spasmogenic activity (21). Both materials 
showed  similar  activity when  injected  into  rabbit  skin,  i.e.,  both  produced  little 
plasma  exudation  in  the  absence  of PGEz;  both  produced  dose-related  plasma 
exudation when  in  the presence of PGE1, and  both  produced  responses that  were 
similarly resistant to the antihistamine, mepyramine maleate. 
These results support  the identification of PAPA as C5a.  However, the carboxyl 
terminal arginine of C5a is rapidly removed by plasma carboxypeptidase, leaving the 
spasmogenically inactive human C5a des Arg (22-24) but spasmogenically active hog 
C5a des Arg (25). PAPA was generated in rabbit plasma in the absence of an inhibitor 
of carboxypeptidase, as was the hog C5a used  in the experiment  described above. 
PAPA is, therefore, most likely to be C5a des Arg. 
Comparison of the Duration of Action of PAPA and Bradykinin in Skin.  PAPA is stable in 
plasma but, in contrast, the permeability-increasing activity of bradykinin (a pol~,- 
peptide inactivated by carboxypeptidase) is abolished by a short incubation in fresh 
rabbit  plasma  (10  min  at  37°C).  Because  of these  findings,  we  investigated  the 
possibility that the duration of action of PAPA in the skin is different from that of 146  HISTAMINE-INDEPENDENT ACTION OF  RABBIT C5a 
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F[~;. 8.  Comparison  of rabbit PAPA  with pure hog C5a. PAPA (Q) was prepared as described in 
the text and hog C5a (C)) was supplied by Professor W. Vogt. Plasma exudation was measured by 
accumulation of intravenously injected '3~I-albumin over a  period of 30 rain after intradermal 
injections.  The responses to both materials were very similar; both produced little exudation in the 
absence of PGEI; both produced dose-related exudation in the presence of PGEI (100 ng/0.1 ml), 
which were similarly resistant to mepyramine (Mep; 1 pg/0.1 ml). Each point represents the mean 
± SEM of six replicate injections.  The horizontal dashed line represents the response to an injection 
of saline. In this experiment, mep~ramine reduced the response to histamine (2.5 #g/0.1 ml) plus 
PGEI by 85%. 
bradykinin. Fig.  9  shows  the  results of such an experiment. Bradykinin and PAPA 
were  injected intradermally at  intervals before the  intravenous injection of labeled 
albumin. PGEx was then injected locally, and exudation was measured over a  period 
of 30 min. It was apparent that bradykinin was rapidly inactivated (tl/2 ffi 4.5 min, in 
this experiment; 5.9 +  0.7 min, n =  seven experiments) whereas PAPA still produced 
marked responses more than 2 h after its injection (tl/2 -- 101 min, in this experiment; 
89 +  11  min, n -- eight experiments). Histamine produced acute responses similar to 
those elicited by bradykinin. 
These experiments further distinguish the activity of PAPA from that of bradykinin 
and histamine. 
Comparison of the  Potencies of PAPA,  Bradykinin, and Histamine.  Fig.  10  shows  a 
comparison of the potencies of PAPA, bradykinin, and histamine in inducing plasma 
exudation over a 30-min period in rabbit skin. In the presence of PGEI, PAPA, at the 
stage  of purification described here,  was  40  times as  active as bradykinin and  160 
times as  active as  histamine. The range of potencies found in six different rabbits 
using three different PAPA preparations was PAPA 5-110 times more potent than 
bradykinin and  60-2,000  times  more  potent  than  histamine. The  wide  ranges  in 
potency ratios are partly a  consequence of differential sensitivity of the skin micro- 
vaseulature of individual rabbits to the different agents. In addition, it was noticeable T.  J.  WILLIAMS  AND  P. J. JOSE  147 
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FIG.  9.  A  comparison of the duration  of action of PAPA and  bradykinin  (BK)  in  rabbit  skin. 
PAPA  (520  ng protein/0.1  ml)  and  bradykinin  (250  ng/0.1  ml)  were injected intradermally  at 
various intervals(shown on the abscissa) before an intravenous injection of lnlI-albumin. PGEI (100 
ng/0.1 ml) was then injected locally, and plasma exudation was measured over a period of 30 rain. 
This experimental design avoids the complication of the effect of PGEI inactivation in the skin. The 
response to bradykinin (C)) was evanescent, the time interval for loss of half the response (h/2)  being 
4.5 rain. In contrast, the response to PAPA (0) was still apparent when PGEI was administered 2 
h after injection of PAPA (tl/2 =  101 min). Each point represents the mean 4- SEM of six replicate 
injections. The dashed line represents the response to two injections of saline with a 60-min interval; 
the small increase produced by addition of PGE~ to the second injection is shown. 
that the slope of the dose-response curve to bradykinin was often more shallow than 
that to PAPA. 
When the three agents were tested in the absence of PG (at doses which produced 
comparable responses in  the presence of PGE1), bradykinin  and  histamine evoked 
plasma exudation but the response to PAPA was very small. This is considered to be 
due to the intrinsic vasodilator activity of bradykinin and histamine in rabbit skin 
(15). In contrast, PAPA was found to produce no significant change in blood flow, as 
measured  by  the  clearance  of intradermally  injected  133Xe. (The  results  of this 
experiment are given in the legend to Fig.  10.) Thus, a vasodilator must be added to 
PAPA in order to elicit significant plasma exudation. PGE2, PGI2, arachidonic acid, 
and adenosine, each of which produces an increase in blood flow in rabbit skin  (11, 
15) similar to that produced by PGEx, also potentiated the plasma exudation response 
to PAPA. These results emphasize that, if PAPA is generated in the skin in response 
to  injected  zymosan,  a  vasodilator substance  (probably a  PG)  must  be  generated 
concomitantly in order to produce the observed plasma exudation. 
Discussion 
Anaphylatoxin was originally proposed to be the mediator of systemic anaphylaxis 
(7).  It was postulated that the bacteriolytic factor present in normal serum, comple- 
ment, cleaved anaphytatoxin from the antigen, a process facilitated by the combina- 
tion of antigen with antibody. Later, it was realized that anaphylatoxin was a product 148  HISTAMINE-INDEPENDENT ACTION OF  RABBIT Cha 
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Fro.  10.  Comparison  of the potency of PAPA, bradykinin,  and  histamine  in  inducing plasma 
exudation  in  rabbit  skin.  PAPA (O), bradykinin  (Bk) (C)), and histamine  (H)  (I)  were  injected 
intradermally, and exudation was measured by the accumulation of previously  administered ~3~I- 
albumin over a  period of 30 min. When compared in the presence  of PGE~ (E);  100 ng/0.1  ml), 
PAPA (at the stage of purification described  and using a molecular weight  of 18,000") was 40 times 
more active than bradykinin and  160 times more active than histamine. In the absence  of PGE~, 
bradykinin and histamine did induce plasma exudation but the response to PAPA was very small. 
Each point represents  the mean +  SEM of six replicate injections.  The dashed line represents  the 
response  to an injection of saline (Sal). The dotted line represents  the response to an injection of 
activated plasma (P*) (1 mg zymosan/ml) plus PGE1; potency ratios were determined at this level. 
Bradykinin and histamine both have some intrinsic  vasodilator activity (t5) that could account for 
their ability to induce plasma exudation  alone.  However, PAPA, which  produced  little plasma 
exudation  when  tested  alone, had  no significant  effect  on  blood  flow as  assessed using  a  ~a'~Xe 
clearance technique (10, 11). The results in terms of percent increase  (+) or decrease  (-) in blood 
flow for six replicate sites were:  PAPA (1.2 X  10  -12 tool), -12.0 3= 5.0%; PAPA (L.2 ×  10  -H mol), 
-9.1  3= 7.9%; and PAPA (1.2 ×  10  -l° mol), -18.6 3= 6.2%. None of these results was significantly 
(unpafired  Student's  t  test)  different  from saline  injected control sites  (0  3=  6.2%).  In  the same 
experiment, norepinephrine (6 ×  10  -11 mol) produced a marked reduction in blood flow: -77.2 3= 
1.7%; and PGE2 (3 ×  10  -l° mol) produced a marked increase  in blood flow: +164.3  3= 14.9%. 
derived  from  complement  itself and  could  be generated  from  serum  (26).  After the 
discovery that  systemic anaphylaxis  could be accounted  for by a  sensitization of cells 
(27,  28), theories involving anaphylatoxin  were largely discarded,  and the conceptual 
difficulties involved in the evolution of an endogenous  toxin were not pursued. 
With  the  later  discovery that  anaphylatoxin  was  a  histamine  releaser  (29),  it was 
possible to link essential features of inflammation, vasodilatation and edema, with the 
complement  system.  This  link  was  considerably  strengthened  by  the  discovery  that 
anaphylatoxins,  now  known  to  be  cleavage  products  of C3  and  C5,  had  powerful 
chemotactic activity for leukocytes in vitro (1,  19, 20).  Histamine release is still widely 
held  to be the link between complement  activation  and  the changes  in blood vessels 
that  occur  in  inflammatory  reactions.  However,  this  proposed  mechanism  severely 
restricts the general importance of complement  to vascular responses because antihis- 
tamines have very limited effects in inflammatory reactions seen clinically or induced 
experimentally  in animals.  The  results presented  here demonstrate  that  complement 
activation can  lead to increased  vascular permeability by a  mechanism  independent T. J.  WILLIAMS AND P. J. JOSE  149 
of histamine release and suggest that  the important substance in this respect is C5a 
des Arg. 
We have attempted to analyze the events occurring in tissues after the introduction 
of inflammatory material. This study was restricted to a  nonallergic model, but we 
consider that  the results obtained here have wider implications. The conclusions of 
this study are summarized below. 
Intradermal injection of zymosan leads to plasma exudation, which is resistant to 
antihistamines  and to inhibitors of kinin  formation. Plasma exudation results from 
the  formation of two chemical  mediators,  both of which  are necessary for plasma 
exudation to proceed (11, 15). The first mediator increases vascular permeability, and 
the second is a  vasodilator substance that  greatly potentiates the plasma exudation 
induced by the first mediator. The vasodilator substance is probably a PG because its 
generation is suppressed by inhibitors of PG synthesis, and its action is mimicked by 
certain prostaglandins.  (Previous experiments [ 11] suggest that the enzymes necessary 
for PG synthesis are normally active in the skin and that blood flow can be regulated 
in an inflammatory reaction by controlling the liberation of the substrate, arachidonic 
acid.) The evidence presented in this paper suggests that the mediator that is involved 
in increasing vascular permeability is a  product of complement activation in extra- 
vascular fluid. Incubation of blood plasma with zymosan results in the generation of 
permeability-increasing activity. However, no vasodilator PG (or stable arachidonic 
acid-releasing substance) is generated by this procedure. For this reason, a PG has to 
be  added  to  the  activated  plasma  in  order  to  produce  plasma  exudation,  thus 
simulating the conditions pertaining when zymosan is injected directly into skin. 
The permeability-increasing activity generated in plasma (PAPA) was purified and 
found to correspond with  the major chemotactic activity in complement-activated 
rabbit plasma, C5a (1), i.e., it produced a dense infiltration of PMN neutrophils when 
injected into rabbit skin and was very active in  three tests on PMN neutrophils in 
vitro. The physicochemical characteristics of PAPA were shown to be similar to the 
C5a anaphylatoxin of other species. However, PAPA was found to have only weak 
spasmogenic  (classical  anaphylatoxic)  activity  on  the  guinea  pig  ileum  and  was, 
therefore, compared with a standard preparation of hog C5a that was purified on the 
basis of its spasmogenic activity (21). The two materials produced similar responses, 
in terms of plasma exudation in rabbit skin: both were dependent on the presence of 
a  vasodilator PG, and both showed a  high resistance to the antihistamine, mepyra- 
mine. 
PAPA  was  stable  in  plasma  and,  therefore,  by  analogy  with  other  species,  is 
presumed to be C5a devoid of its carboxyl terminal arginine, i.e., C5a des Arg. The 
stability of PAPA in plasma, and presumably in tissue fluid, may contribute to the 
high potency of the material when compared (in  the presence of a  vasodilator PG) 
with  that  of the  established  permeability-increasing  compounds,  bradykinin  and 
histamine. It was observed that the activity of PAPA was of remarkably long duration 
in the skin when compared with  the evanescent responses produced by bradykinin 
and histamine. 
From  these  results  we  can  postulate  the  initial  series  of events  occurring when 
microorganisms enter tissues of the nonsensitized animal. The first event is recognition 
of foreign cell walls, a  process which involves complement present  in extravascular 
tissue  fluid. Complement-mediated lysis of the foreign cells can  then proceed very 150  HISTAMINE-INDEPENDENT ACTION OF  RABBIT  C5a 
quickly,  the  degree  of cell  killing  depending  on  the  defense  mechanisms  of the 
microorganism itself. Because the quantity of extravascular tissue fluid (and therefore 
the quantity of complement) is limited, a supply of plasma to the tissue in proportion 
to the stimulus size (i.e., proportional to the number of microorganisms) is essential. 
This requirement may explain the evolution of mechanisms for increasing vascular 
permeability utilizing one of the side products of complement activation, C5a, as a 
local hormone. This functional interpretation of edema is strengthened by the older 
observations that the maximal rate of killing of bacteria is within 2 h of injection into 
skin  (30,  31),  which  corresponds  with  the  period of maximal  plasma  exudation 
reported here. 
The  local  extravascular  generation  of C5a  can  control  vascular  permeability. 
However, in our model, a concomitant generation of vasodilator PG is obligatory in 
order to produce plasma exudation. (Factors governing the release of the arachidonic 
acid  substrate  remain  unknown,  but  none of the  stable  products of complement- 
activated plasma appear to release arachidonic acid, i.e., activated plasma does not 
produce  vasodilation  as  does  arachidonic  acid.)  Leukocytes, predominantly  PMN 
neutrophils, accumulate over a  more protracted time-course than that observed for 
plasma exudation. These cells are involved in the phagocytosis of material derived 
from the earlier cytolytic process and in killing those organisms which have resisted 
the cytolytic phase. Previous observations (1) suggest that C5a is the most important 
mediator of leukocyte accumulation derived from blood plasma.  (Products of arach- 
idonic acid derived from the lipoxygenase pathway, e.g., 5,12-dihydroxy-eicosatetrae- 
noic acid, may also contribute to leukocyte accumulation [32].)  Thus, extravascular 
generation of C5a  may be important  for both  fluid  and  cell accumulation  in  the 
inflammatory reaction, and it is of interest that  C5a des Arg appears  to be highly 
active in both processes. 
Although we have used a simple nonallergic model, we suggest that the cooperation 
between  a  PG  and  C5a  to  produce  edema  may  be  relevant  to  many  types  of 
inflammatory reaction. In some animal models of tissue trauma, edema is suppressed 
by inhibitors of PG synthesis (33), and damaged tissues have been shown to activate 
plasma  complement  in  vitro  (34).  In  acute  allergic  reactions,  such  as  the  Arthus 
reaction, edema is suppressed by inhibitors of PG synthesis (35, 36) and by depletion 
of complement (37). Similar interactions may occur in chronic inflammation because 
macrophages residing in tissues can synthesis PG (38, 39) and complement components 
(40, 41).  Our observations have been interpreted as  representing part  of a  defense 
process in which the components of the inflammatory process are assembled in order 
to  remove  a  potentially  hazardous  stimulus,  and  are  then  disassembled  after  its 
elimination. However, the general principles expressed may be relevant to chronic, 
self-destructive inflammatory  reactions  that  may  reflect  a  failure of the  chemical 
control systems. 
Summary 
Intradermal  injection of zymosan into nonsensitized rabbits induces plasma exu- 
dation, which is dependent on two mediators: C5a generated in extravascular tissue 
fluid  and  a  vasodilator  prostaglandin  generated  from  substrates  localized  in  cell 
membranes. This relationship between the complement system and the prostaglandin 
synthesis system has not  previously been explored, and complement activation has T. J.  WILLIAMS AND  P. J. JOSE  151 
generally been associated with increased vascular permeability via histamine release. 
We  report  that  C5a  increases  vascular  permeability  by  a  mechanism  that  is  not 
dependent  on histamine release; however plasma exudation is virtually undetectable 
in the absence of a vasodilator substance. Because the permeability-increasing activity 
is stable in plasma, analogy with other species suggests that the activity is a  result of 
C5a devoid of its carboxyl terminal arginine (C5a des Arg). This relates the observed 
permeability-increasing  activity with  effects on leukocytes rather  than  effects as an 
anaphylatoxin. 
We are indebted to Professor W. Vogt, Max Planck Institut, G6ttingen, G.F.R., for the generous 
gift  of hog C5a;  Dr.  D.  Male,  Middlesex  Hospital  Medical  School,  London,  for the  SDS 
polyacrylamide gel electrophoretic analyses; and M. J. Peck for excellent technical assistance. 
Received  for publication 25July 1980 and in revised  form 29 September 1980. 
References 
I.  Snyderman, R., J.  Phillips,  and S. E. Mergenhagen.  1970. Polymorphonuclear leukocyte 
chemotactic activity in rabbit serum and guinea pig serum treated with immune complexes: 
evidence for C5a as the major chemotactic factor. Infect. Immun. 1:521. 
2.  Valiota, E. H., and H. J. Mfiller-Eberhard. 197:3. Formation of  C3a and C5a anaphylatoxins 
in whole human serum after inhibition of the anaphylatoxin inactivator. J. Exp.  Med.  137: 
1109. 
3.  Hugli,  T.  E.,  and  H.  J.  Mfiller-Eberhard.  1978. Anaphylatoxins:  C3a  and  C5a.  Adv. 
lmmunol. 26:1. 
4.  Dias da Silva, W., and I. H. Lepow. 1967. Complement as a mediator of inflammation. II. 
Biological  properties  of anaphylatoxin  prepared  with  purified  components  of human 
complement.J. Exp.  Med.  125:921. 
5.  Cochrane,  C.  G.,  and  H.  J.  Mfiller-Eberhard.  1968. The  derivation  of two  distinct 
anaphylatoxin activities from the third and  fifth components of human complement. J. 
Exp.  Med.  127:371. 
6.  Nicholson,  A.,  D.  T.  Fearon,  and  K.  F.  Austen.  1978. Complement.  In  Handbook  of 
Experimental  Pharmacology. J.  R.  Vane  and  S.  H.  Ferreira,  editors.  Springer-Verlag, 
Berlin-Heidelberg-New York. 50:425. 
7.  Friedberger,  E.  1910. Weitere  Untersuchungen  fiber Eiweissanaphylaxie.  Z.  lmmunitaets- 
forsch. 4:636. 
8.  Williams,  T. J.  1978. A  proposed  mediator of increased  vascular permeability  in acute 
inflammation in the rabbit. J. Physiol. (Lord.).  281:44. 
9.  Jose,  P. J.,  M. J.  Peck,  C.  Robinson,  and  T. J.  Williams.  1978. Characterization  of a 
histamine-independent  vascular permeability-increasing factor generated on exposure of 
rabbit plasma to zymosan.J. Physiol. (Lord.).  281:13. 
10.  Williams, T.J. 1976. Simultaneous measurement of local plasma exudation and blood flow 
changes induced by intradermal injection of vasoactive substances, using [lSll]aibumin and 
l'~*Xe.J. Physiol. (Lord.). 254:4. 
11.  Williams,  T.  J.  1979. Prostaglandin  E2,  prostaglandin  I2 and  the  vascular  changes  of 
inflammation. Br. J. Pharmacol. 65:517. 
12.  Mejbaum-Katzenellenbogen,  W., and W. M. Dobryszycka. 1959. New method for quan- 
titative  determination  of serum  proteins  separated  by paper electrophoresis.  Clin. Chim. 
Acta. 4:515. 
13.  Andrews,  P.  1964. Estimation  of the  molecular  weights  of proteins  by  Sephadex  gel- 
filtration. Biochem. J. 91:222. 152  HISTAMINE-INDEPENDENT ACTION OF  RABBIT  C5a 
14.  Williams, T. J., and J. Morley. 1973. Prostaglandins as potentiators of increased vascular 
permeability in inflammation. Nature (Lond.).  246:215. 
15.  Williams, T. J., and M. J.  Peck.  1977. Role of prostaglandin-mediated vasodilatation in 
inflammation. Nature (  Lond. ). 270:530. 
16.  Bodammer,  G.,  and  W.  Vogt.  1970. Beeinflussung  der  Capillarpermeabilit~it in  der 
Meerschweinchenhaut  durch  Anaphylatoxin  (AT)  Naunyn-Schmiedebergs  Arch.  Pharmakol. 
266:255. 
17.  Laemmli, U. K.  1970. Cleavage of structural proteins during the assembly of the head of 
bacteriophage T4. Nature (Lond.).  227:680. 
18.  Henson, P. M., K. McCarthy, G. L. Larsen, R. O. Webster, P. D. Gicias, R. B. Dreisin, T. 
E.  King,  and  J.  O.  Shaw.  1979. Complement  fragments,  alveolar  macrophages,  and 
alveolitis. Am. J. Pathol.  97:93. 
19.  Fernandez, H. N., P. M. Henson, A. Otani, and T. E. Hugli. 1978. Chemotactic response 
to human C3a and C5a anaphylatoxins. 1. Evaluation of C3a and C5a leukotaxis m vitro 
and under simulated in vivo conditions..]'. ImmunoL  120:109. 
20.  Ward, P. A., T. E. Hugli, and D. E. Chenoweth.  1979. Complement and chemotaxis. In 
Handbook of Inflammation. Vol. 1. L. E. Glynn, J. C. Houck, and G. Weissmann, editors. 
Elsevier/North-Holland Biomedical Press, Amsterdam. 153. 
21.  Vogt, W. 1968. Preparation and some properties ofanaphylatoxin from hog serum. Biochem. 
Pharmacol.  17:727. 
22.  Bokisch, V.  A., and  H. J.  Miiller-Eberhard.  1970. Anaphylatoxin inactivator of human 
plasma: its isolation and characterization as a carboxypeptidase.J. Clin.  Invest.  49:2427. 
23.  Fernandez, H. N., and T. E. Hugli. 1976. Partial characterization of human C5a Anaphy- 
latoxin. I. Chemical description of the carbohydrate and polypeptide portions of human 
C5a.J. Immunol.  117:1688. 
24.  Fernandez, H. N., and T. E. Hugli.  1978. Primary structural analysis of the polypeptide 
portion of human C5a anaphylatoxin.J. Biol.  Chem. 253:6955. 
25.  Damerau,  B.,  B.  Zimmermann,  and  W. Vogt.  1980. Comparison of hog C5a  and  C5a- 
desArg preparations: evidence for intrinsic spasmogenic and other biological activities of 
C5a-desArg. J. lmmunol.  124:1517. 
26.  Novy, F. G., and P. H. DeKruif. 1917. Anaphylatoxin and anaphylaxis.J. Am. Med. Assoc. 
68:1524. 
27.  Schultz, H. E. 1910. Physiological studies in anaphylaxis. I. The reaction of smooth muscle 
of the guinea pig sensitised with horse serum.J. Pharmacol. Exp.  Ther.  1:549. 
28.  Dale, H. H. 1913. The anaphylactic reaction of plain muscle in the guinea pig.J. Pharmacol. 
Exp.  Ther. 4:167. 
29.  Hahn,  F., and  A. Oberdorf.  1950. Antihistaminica und  anaphylaktoide Reaktionen. Z. 
Immunitaetsforsch.  107:528. 
30.  Miles, A. A., E. M. Miles, and J. Burke. 1957. The value and duration of defence reactions 
of the skin to the primary lodgement of bacteria. Br. J. Exp.  Pathol.  38:79. 
31.  Burke, J.  F., and A. A. Miles.  1958. The sequence of vascular events in early infective 
inflammation.J. Pathol.  Bacteriol.  76:1. 
32.  Ford-Hutchinson, A. W., M. A. Bray, M.  V. Doig, M.  E. Shipley, and  M. J.  H. Smith. 
1980.  Leukotriene  B  a  pot.ent  chemokinetic  and  aggregating  substance  released  from 
polymorphonuclear leucocytes. Nature  (Lond.).  286:264. 
33.  Arturson,  G.,  and  C.-E. Jonsson.  1973. Effects  of indomethacin  on  the  transcapillary 
leakage of macromolecules and the efflux of prostaglandins in the paw lymph following 
experimental scalding injury. Ups. J. Med.  Sci.  78:181. 
34.  Heideman, M., B. Kaijser, and L-E. Gelin. 1978. Complement activation and hematologic, 
hemodynamic and respiratory reactions early after soft-tissue injury.J.  Trauma.  18:696. T. J.  WILLIAMS AND  P. J. JOSE  153 
35.  Blackham, A., J.  B.  Farmer, H. Radziwonik, and J. Westwick. 1974. The role of prosta- 
glandins in rabbit monoartieular arthritis. Br. J. Pharmacol. 51:35. 
36.  Butler,  K., and  G.  P.  Lewis.  1976. The  effect of anti-inflammatory compounds  on  the 
biochemical changes in the Arthus reaction. J. Pathol. 119"175. 
37.  Osier, A. G., M. M. Hawrisiak, Z. Ovary, M. Siqueira, and O. G. Bier. 1957. Studies on the 
mechanism of hypersensitivity phenomena. II. The participation of complement in passive 
cutaneous anaphylaxis of the albino rat.J. Exp.  Med.  106:811. 
38.  Humes, J. L., R.J. Bonney, L. Pelus, M. E. Dahlgren, S. J. Sadowski, F. A. Kuehl, and P. 
Davies.  1977. Macrophages synthesise and release prostaglandins in response to inflam- 
matory stimuli. Nature (Lond.). 269:149. 
39.  Bray, M.  A., and  D. Gordon.  1978. Prostaglandin production by macrophages and  the 
effect of anti-inflammatory drugs. Br. J. Pharmacol. 63:635. 
40.  Cohen, H. R.  1974. Biosynthesis of serum complement. Prog. Immunol. 1:183. 
41.  Unanue, E. R.  1976. Secretory function of mononuclear phagocytes. Am. J. Pathol. 83:396. 